000181161 001__ 181161
000181161 005__ 20240229145642.0
000181161 0247_ $$2doi$$a10.3390/cancers14153836
000181161 0247_ $$2pmid$$apmid:35954499
000181161 0247_ $$2altmetric$$aaltmetric:134012723
000181161 037__ $$aDKFZ-2022-01814
000181161 041__ $$aEnglish
000181161 082__ $$a610
000181161 1001_ $$0P:(DE-HGF)0$$aHeisser, Thomas$$b0$$eFirst author
000181161 245__ $$aTreatment Costs of Colorectal Cancer by Sex and Age: Population-Based Study on Health Insurance Data from Germany.
000181161 260__ $$aBasel$$bMDPI$$c2022
000181161 3367_ $$2DRIVER$$aarticle
000181161 3367_ $$2DataCite$$aOutput Types/Journal article
000181161 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1674136449_2814
000181161 3367_ $$2BibTeX$$aARTICLE
000181161 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000181161 3367_ $$00$$2EndNote$$aJournal Article
000181161 500__ $$a#EA:C070#EA:C070#LA:C120#
000181161 520__ $$aObjective: Evidence on the cost-effectiveness of screening for colorectal cancer (CRC) in the German general population remains scarce as key input parameters, the costs to treat CRC, are largely unknown. Here, we provide detailed estimates on CRC treatment costs over time. Methods: Using insurance claims data from the Vilua healthcare research database, we included subjects with newly diagnosed CRC and subjects who died of CRC between 2012 and 2016. We assessed annualized CRC-related inpatient, outpatient and medication costs for up to five years after first diagnosis and prior to death, stratified by sex and age. Findings: We identified 1748 and 1117 subjects with follow-up data for at least 1 year after diagnosis and prior to death, respectively. In those newly diagnosed, average costs were highest in the first year after diagnosis (men, EUR 16,375-16,450; women, EUR 10,071-13,250) and dropped steeply in the following years, with no consistent pattern of differences with respect to age. Costs prior to death were substantially higher as compared to the initial phase of care and consistently on a high level even several years before death, peaking in the final year of life, with strong differences by sex and age (men vs. women, <70 years, EUR 34,351 vs. EUR 31,417; ≥70 years, EUR 14,463 vs. EUR 9930). Conclusion: Once clinically manifest, CRC causes substantial treatment costs over time, particularly in the palliative care setting. Strong differences in treatment costs by sex and age warrant further investigation.
000181161 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000181161 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000181161 650_7 $$2Other$$acolorectal cancer
000181161 650_7 $$2Other$$acost-effectiveness
000181161 650_7 $$2Other$$aeconomic burden
000181161 650_7 $$2Other$$ahealthcare costs
000181161 650_7 $$2Other$$ascreening
000181161 7001_ $$00000-0001-9128-6304$$aSimon, Andreas$$b1
000181161 7001_ $$aHapfelmeier, Jana$$b2
000181161 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b3$$udkfz
000181161 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4$$eLast author$$udkfz
000181161 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers14153836$$gVol. 14, no. 15, p. 3836 -$$n15$$p3836$$tCancers$$v14$$x2072-6694$$y2022
000181161 909CO $$ooai:inrepo02.dkfz.de:181161$$pVDB
000181161 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000181161 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000181161 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000181161 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000181161 9141_ $$y2022
000181161 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000181161 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000181161 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000181161 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000181161 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000181161 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000181161 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2021$$d2022-11-30
000181161 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-30
000181161 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-30
000181161 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-01-24T07:56:58Z
000181161 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-01-24T07:56:58Z
000181161 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-01-24T07:56:58Z
000181161 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-30
000181161 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-30
000181161 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-30
000181161 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-30
000181161 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-30
000181161 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2021$$d2022-11-30
000181161 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000181161 9202_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000181161 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000181161 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000181161 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000181161 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000181161 980__ $$ajournal
000181161 980__ $$aVDB
000181161 980__ $$aI:(DE-He78)C070-20160331
000181161 980__ $$aI:(DE-He78)C120-20160331
000181161 980__ $$aI:(DE-He78)HD01-20160331
000181161 980__ $$aUNRESTRICTED